summari report sale
organ growth adjust ep report sale beat
consensu adj ep in-lin
 acceler came
estim addit introduc guidanc
organ revenu growth adjust ep
view robust outlook view deliv three key
messag call remain confid libr
approv posit increment commentari
updat timelin provid expect sustain current
level organ growth execut divers
pipelin remain select regard
chang estim price target rais
sale estim organ
maintain adjust ep estim rais
sale estim organ
trim adj ep estim increas
price target
sale beat ep line report sale
organ growth adjust ep adjust
ep in-lin consensu estim guidanc
rel model in-lin ep larg reflect
higher opex vs estim slightli lower
gross margin vs estim off-set lower tax
rate vs model report revenu
beat consensu estim organ
sale growth ex-fx acceler
came estim note fx
bp headwind report sale better
model
broad base strength organ sale growth us sale
organ beat estim ou sale
organ beat estim
nutrit sale beat consensu
estim organ nutrit growth acceler
driven strong growth across sever countri
side busi pediatr adult specif
mention experienc strong growth southeast asia
latin america though china continu experi soft
said manag note overli reliant china
develop plan increas success region
continu follow page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort intang ep continu
oper ep includ stj amo alr deal
compani data secur llc estim reuter
continu previou page
diagnost dx sale slightli ahead consensu slightli
forecast organ growth slow reflect faster growth lab
slightli off-set slower expect molecular vs point
vs rapid diagnost vs attribut strength
lab alin roll europ segment impact ngo non-
government organ tender africa
medic devic sale similar consensu estim report
basi organ growth acceler vs
estim importantli perform key growth driver mitraclip libr basic line
exceed expectations- mitraclip sale came vs estim libr sale
came vs estim
epd establish pharmaceut sale slightli consensu
forecast organ growth acceler manag
note continu execut strategi emerg market specif latin america asia
yet anoth strong quarter medic devic post anoth strong quarter med
devic organ growth acceler vs growth growth
devic growth led diabet organ structur heart heart
failur electrophysiolog diabet robust libr growth ww
organ continu intern market see detail structur heart
perform quarter led mitraclip grew organ world-wide
sale us us benefit
reimburs year compani believ arriv sometim ou mitraclip
post sale repres growth ex-fx mitraclip ou ex-fx growth
show stabil vs improv rel view
posit trend go neg impact mitra-fr current model
mitraclip ww sale ex-fx ex-fx
robust libr growth continu confid fda approv libr icgm libr
 adopt continu robust trajectori compani post sale
estim repres sequenti y/i growth ou
libr print line estim repres ex-fx y/i growth
regard libr still work open item fda though manag note
compani pleas progress made updat timelin provid
remain confid perform libr receiv fda approv libr well
icgm design believ commentari today call increment posit
statu libr look abt focu continu drive robust demand direct
consum dtc advertis partnership sale personnel oper front support
strong patient demand continu invest ad libr manufactur capac current
model libr ww sale ex-fx ex-fx
neuromodul improv quarter sign stabil neuromodul nmd
acceler vs importantli two headwind
experienc start appear stabil extent first note
spinal cord stimul salesforc execut issu stabil quarter rel around
abt sale rep new team year compani note time
spent get cohort speed larg complet second broader market slowdown
impact nmd busi throughout believ market stabil
degre specif compani note innov fuel market improv
multipl compani come new product note proclaim xr system came
earli believ impact quarter
vascular growth improv quarter post improv vascular growth
organ growth vs recal compani wind parti arrang
royalti manufactur agreement continu impact busi
guidanc introduc today call introduc top bottom-lin guidanc
compani expect organ sale growth view robust outlook
regard currenc manag expect headwind report sale headwind
ep look abt top-lin guidanc busi epd expect grow mid-to-high
singl digit nutrit expect grow around dx expect grow mid-to-high singl
digit med devic expect grow doubl digit level similar move
 expect gross margin sg sale
sale adjust tax rate bottom line compani issu adjust ep
guidanc bracket consensu
expect adjust ep organ sale growth current
rate expect neg impact littl report sale busi
top line expect epd mid high singl digit nutrit dx mid-to-high-singl
digit med devic doubl digit level similar expect
gross margin somewhat sale somewhat sale adjust sg
around sale
messag chang recal past year focus
pay debt stj alr acquisit compani net debt ebitda
provid compani signific financi flexibl view howev manag note
call expect philosophy/framework go forward name compani
look deal unless strateg meet threshold manag note continu
believ diversifi approach strong confid intern pipelin addit
note share repurchas author typic use off-set dilut well
consist histori increas dividend
price target
price target base ep estim risk target
includ slower growth key busi market delay stj alr integr slower
expect continu deliv double-digit underli ep growth mid high-singl digit
underli sale growth oper leverag
abbott laboratori diversifi global medic product compani four key busi segment
nutrit diagnost establish pharmaceut epd medic devic compani report
total revenu compani acquir stj januari nearli doubl
metricswfconsensuswfconsensusseg pharmaceut compani report secur llc estim factset visibl alpha explicitli state consensu visibl alpha may vari base broker contribut actual vs actual vs medic technolog
